Review

FMRP and CYFIP1 at the synapse and their role in psychiatric vulnerability

Nicholas E Clifton\textsuperscript{1,2}, Kerrie L Thomas\textsuperscript{1,3}, Lawrence S Wilkinson\textsuperscript{1,4}, Jeremy Hall\textsuperscript{1,2,5}, Simon Trent \textsuperscript{1,6}

1. Neuroscience & Mental Health Research Institute, Hadyn Ellis Building, Cardiff University, CF24 4HQ
2. MRC Centre for Neuropsychiatric Genetics and Genomics, School of Medicine, Hadyn Ellis Building, Cardiff University, CF24 4HQ
3. School of Biosciences, Cardiff University, The Sir Martin Evans Building, Museum Avenue, Cardiff, CF10 3AX
4. School of Psychology, Cardiff University, University, Tower Building, 70 Park Place, Cardiff, CF10 3AT
5. Division of Psychological Medicine and Clinical Neurosciences, School of Medicine, Cardiff University, CF14 4XN
6. Huxley Building, School of Life Sciences, Faculty of Natural Sciences, Keele University, ST5 5BG

\textbf{Short Title:} Synaptic FMRP & CYFIP1 and psychiatric disorders

\textbf{Corresponding Author:}

Dr Simon Trent
Lecturer in Neuroscience (& Honorary Senior Research Fellow at Cardiff University)

026 Huxley Building
School of Life Sciences
Faculty of Natural Sciences
Keele University
Staffordshire
ST5 5BG

Tel: +44 (0)1782 733497
Email: s.trent@keele.ac.uk

\textbf{Keywords:} FMRP, CYFIP1, FMRP targets, synapse, psychiatric disorders
Abstract

There is increasing awareness of the role genetic risk variants have in mediating vulnerability to psychiatric disorders such as schizophrenia and autism. Many of these risk variants encode synaptic proteins, influencing biological pathways of the postsynaptic density and, ultimately, synaptic plasticity. Fragile X Mental Retardation 1 (FMR1) and Cytoplasmic FMRP-Interacting Protein (CYFIP1) contain two such examples of highly penetrant risk variants and encode synaptic proteins with shared functional significance. In this Review, we will discuss the biological actions of FMRP and CYFIP1, including their regulation of i) protein synthesis and specifically FMRP targets, ii) dendritic and spine morphology and iii) forms of synaptic plasticity such as long-term depression. We draw upon a range of preclinical studies that have used genetic dosage models of FMR1 and CYFIP1 to determine their biological function. In parallel, we discuss how clinical studies of Fragile X Syndrome or 15q11.2 deletion patients have informed our understanding of FMRP and CYFIP1 proteins, and highlight the latest psychiatric genomic findings that continue to implicate FMRP and CYFIP1. Lastly, we assess the current limitations in our understanding of FMRP and CYFIP1 biology and how they must be addressed before mechanism-led therapeutic strategies can be developed for psychiatric disorders.

1. The synapse and postsynaptic density proteins

Neurotransmission between presynaptic and postsynaptic terminals is the adaptive communication mechanism linking neurons and other cell types into neural circuits and networks, which form the basis of synaptic plasticity, cognition and behaviour (1,2). The majority of excitatory, glutamatergic synapses in the mammalian brain are located at small dendritic protrusions, or spines (3), and contain a prominent assembly of proteins at the postsynaptic membrane known as the postsynaptic density (PSD) (4,5). Proteomic profiling of the PSD has revealed over 1000 different proteins (6–8), many of which converge on the regulation of synaptic plasticity through biological pathways controlling protein synthesis, receptor trafficking or structural rearrangements (9–11).

2. Synaptic FMRP: regulator of mRNA and local translation
One such synaptic protein is Fragile-X Mental Retardation Protein (FMRP), encoded by the \textit{FMR1} gene (Xq27.3)(12) and the monogenic cause of neurodevelopmental disorder Fragile X Syndrome (FXS) (13). FMR1 mRNA is expressed in the neuronal cell body, developing and mature axons, dendrites and dendritic spines, as well as the nucleus (14,15), but not across all neuronal populations (16,17). FMRP is a RNA binding protein (RBP) with multiple structural motifs for binding RNA (such as KH domain and RGG box) (18), capable of regulating the dendritic sequestering, and localisation, of hundreds of target neuronal mRNAs (19,20), either through direct interactions or via intermediary interactions with noncoding RNA (21,22).

FMRP, its target mRNA and other protein partners, together form large messenger ribonucleoparticles (mRNPs) (23). Within the mRNP, FMRP plays a key role in the translational silencing of its target mRNA (24–27), required during the transport of mRNA along dendrites (28), before synaptic activation results in the docking of the mRNPs to the spines and subsequent translation (29,30). FMRP specifically regulates the rate-limiting step of cap-dependent mRNA translation \textit{initiation} by binding to the initiation factor eIF4E and FMRP-binding partner CYFIP1 (see \textbf{Section} 4 later) (31,32), although initiation may also be regulated via FMRP ubiquitination or sumoylation (33–35). FMRP also controls \textit{elongation} stages of mRNA translation by stalling ribosomes on FMRP target transcripts (19,24), although how FMRP switches between the regulation of initiation and elongation is currently unknown (36). FMRP is therefore a critical mediator of local translation of mRNA targets, acting at both presynaptic and postsynaptic terminals (24,37,38). Some of the key biological roles of FMRP at postsynaptic terminals are highlighted in \textbf{Figure 1}.

Beyond translational silencing, FMRP plays other biological roles (39) including RNA editing (40), the regulation of mRNA target stability (41), and ion-channel binding (42,43), collectively influencing calcium signalling (44), activity-dependent neurodevelopment (45) and the balance of excitatory/inhibitory circuits (46,47). The additional functions of FMRP might explain instances where FMRP does not appear to be a straightforward repressor of protein synthesis (48), perhaps most pertinently through FMRP’s ability to influence the stability of a subset of mRNAs (22,49).
3. FMRP targets

Considerable effort has been made to identify the mRNAs targeted by FMRP so that biological pathways affected by mutations in FMR1 can be better predicted. Such studies have used immunoprecipitation followed by either microarray (50,51) or high-throughput sequencing (19,52) to determine FMRP-bound mRNAs. Due to varied methodology and tissues (as well as influence from type I and II errors), these lists of FMRP targets differ considerably (52,53). Therefore, precisely which mRNAs are bound by FMRP is uncertain and likely to be somewhat tissue-specific. Two studies using mouse cortical tissue and comparable methodology (high-throughput sequencing of RNA isolated by crosslinking immunoprecipitation) yielded highly overlapping results: 89% of mRNAs identified as FMRP targets by Darnell and colleagues (19) were also identified by Maurin et al (52). Still, only a small subset of the proposed targets have been validated (23,49,54–57).

Gene ontology analyses of brain-derived FMRP targets confirm an overrepresentation of genes involved in functions related to synaptic activity, plasticity, development and anatomy (19,52,58), consistent with studies of FMRP function. The proteins they encode include both presynaptic and postsynaptic components. Of these are subunits and interactors of receptor complexes considered central to synaptic plasticity phenotypes associated with FXS, chiefly the mGluR5 and NMDA receptor signalling complexes (19). The observation that FMRP binds some presynaptic proteins supports evidence that FMRP regulates protein synthesis during axon development and synapse formation (59–62).

Whilst studies of FMRP targets have identified probable interactions between FMRP and ribosomal mRNAs, further work is needed to determine whether the translation of these mRNAs are indeed repressed by FMRP within the regulatory complex together with CYFIP1 and eIF4E proteins in the cell (31,32).

4. Synaptic CYFIP1: a negative regulator of protein synthesis and cytoskeletal dynamics

Cytoplasmic FMRP-Interacting Protein (CYFIP1) is a highly dynamic synaptic protein involved in numerous biological pathways through an array of protein-protein interactions (Figure 1) (63). Originally known as a Specifically Rac1 Activated protein 1 (SRA-1)(64), CYFIP1 was later found to bind with FMRP (12,65), forming a critical CYFIP1-FMRP complex at the synapse (31). Specifically, FMRP-bound CYFIP1 acts as a non-canonical eIF4E-binding protein (4E-BP) (31), thereby providing competition for the binding of eIF4E to the translation initiation
complex (eIF4E-eIF4G) (66,67). Overall, it is this eIF4E-CYFIP1-FMRP complex, together with its target mRNA, that represses translation at dendritic and synaptic sites (31). Upon synaptic activation via Tropomyosin receptor kinase B (TrkB) or group I mGluRs, eIF4E is released from CYFIP1-FMRP, and permits the translation of target mRNAs (31). A subsequent study has implicated a MAP-kinase-interacting kinase (MNK)-dependent pathway in the release of the inhibitory CYFIP1-FMRP complex from target mRNA, via MNK phosphorylation of CYFIP1 protein, in the early phase of LTP, thereby permitting translation (68).

Aside from its role in regulating protein synthesis, CYFIP1 forms part of the ~400kDa heteropentameric WAVE regulatory complex, which also contains WAVE1/2/3, ABI1/2, NCKAP1 and HPSC300 components (69). Without CYFIP1, the WAVE complex promotes actin cytoskeleton remodelling via the Arp2/3 complex (70–72), impacting on aspects of dendritic spine formation, stability, morphology, migration and excitability (73). The role of CYFIP1 is to maintain the WAVE complex in an inhibited state, until the GTPase, Rac1, causes the dissociation of CYFIP1 from the WRC and allows actin remodelling to proceed via Arp2/3 (74).

CYFIP1 belongs to the two aforementioned complexes, FMRP and WAVE, in a mutually exclusive manner, skewed towards greater association with the WAVE complex, under basal conditions (74). Notably, synaptic activation changes the protein conformation of CYFIP1, from globular to planar, and drives the distribution of CYFIP1 protein further towards the RAC1-WAVE complex, with a concomitant decrease in the eIF4E-CYFIP1 complex (71,74,75). Therefore, CYFIP1 is a central molecular mediator that bridges the two processes of mRNA translation and actin dynamics, both essential for synaptic plasticity (76–78). Other molecular roles for CYFIP1 are being explored, including its role presynaptically. For instance, presynaptic function is altered in the hippocampus of juvenile Cyfip1 KO mice, thought to derive from changes in presynaptic terminal size and enhanced vesicle release probability, and driven by dysregulation of the WAVE complex (79). These findings closely align with previous findings in cyfip1 mutant fly models that specifically found alterations in actin polymerisation in presynaptic terminals. (65,80). More recently, Cyfip1 KO mice were found to have decreased myelination of callosal axons, alongside impaired presynaptic neurotransmission in the corpus callosum (81).

CYFIP1 has a closely related parologue, CYFIP2, with over 88% amino acid identity (12). Like CYFIP1, CYFIP2 is found at excitatory (82) and inhibitory (83) synapses, and binds both to the WAVE complex (63,69) and to FMRP.
Interestingly, CYFIP2 additionally binds to FMRP-related proteins, FXR1P and FXR2P, while CYFIP2 mRNA is a target of FMRP (19), implying a further layer of feedback between FMRP and the family of CYFIP proteins. However, the molecular redundancy between these paralogues is limited, given that the deletion of both copies of CYFIP1 is embryonically lethal (74,84). Furthermore, CYFIP1, but not CYFIP2, has been consistently associated with neuropsychiatric disorders (82,83), although see (85).

5. Psychiatric disorders and the synapse

Considerable evidence suggests that a wide range of neuropsychiatric disorders such as FXS, Autism Spectrum Disorders (ASDs), schizophrenia, intellectual disabilities (ID), and bipolar disorder exhibit convergent synaptic pathology (6,32,86–91). Synaptic dysfunction has been observed at several levels including: genetic alterations (92–94); aberrant proteins (95) and their translation (25,96–98); molecular signalling pathways (99–101); spine morphology (102); aberrant synaptic plasticity (103–105); neurocircuitry and connectivity (106). These interrelated observations highlight impaired synaptic function as a common feature of several neuropsychiatric disorders (91,94,107).

In light of this view, and the biological importance of FMRP and CYFIP1 at the synapse (outlined in Sections 2 and 4), we will now consider the role of FMRP and CYFIP1 in the aetiology of psychiatric disorders, using data from human patient studies, especially psychiatric genomics, and preclinical models.

6. FMRP and FMRP targets in psychiatric disorders

6.1 FXS patients and Fmr1 knockout models

In humans, the transcriptional silencing of the FMR1 gene by a triplet repeat expansion (beyond 200 repeats, typically ~800) in the 5'-untranslated region of FMR1 (108) leads to FXS (13,109). FXS patients display a broad range of abnormalities including increased immaturity of dendritic spines (110–112); altered molecular signalling (23); increased levels of basal protein synthesis (113,114); altered neuron and circuit excitability (115); structural and connectivity defects in brain networks (116); and a range of cognitive and behavioural phenotypes that overlap considerably with intellectual disability and ASD (117–119). Indeed, FXS represents the single most common form of inherited ID with a prevalence of 1:4,000 males and 1:8,000 females (120) and the most

Downloaded by: 54.70.40.11 - 3/25/2020 8:57:37 PM
common, single-gene cause of ASD (108,117). FMRP may also be involved in other neuropsychiatric disorders, beyond FXS and related ASDs, including schizophrenia and bipolar disorder (121–125).

The effects of Fmr1 mutations have been interrogated preclinically for 25 years through the Fmr1 knockout (KO) mouse model (126), and with the advent of modern gene-targeting technologies, the Fmr1 KO rat model (127,128). Many of the features of human FXS have been recapitulated in Fmr1 KO mouse and rat models, especially in three key areas: dendritic spine maturation (112,127,129,130); elevated basal protein synthesis (127,131–133); and behavioural/cognitive phenotypes, including ASD-like abnormalities (134), abnormalities in social interaction and interest (135), social anxiety (136) and reduced behavioural flexibility/reversal learning in a variety of tasks (127,137–141).

In addition to heightened global protein synthesis, Fmr1 KO rodents display a lack of metabotropic glutamate receptor (mGluR)-dependent translational control, which results in an elevated protein synthesis-dependent form of synaptic plasticity, known as metabotropic glutamate receptor (mGluR)-mediated long-term depression (127,142–145). Increased mGluR-dependent translation is thought to occur through excessive activation of the mGluR5 subtype, given that reductions in mGluR5 expression (132), or the mGluR5 antagonist MPEP (46,146), can rescue several Fmr1 KO phenotypes. The altered mGluR5 signalling in the absence of Fmr1 appears to be mediated through the preferential interaction of mGluR5 with activity-dependent isoforms of Homer1 over constitutive Homer proteins (147,148).

The deletion of Fmr1 results in the loss of the repressive elf4E-Cyfip1-FMRP complex, which de-represses the initiation complex, elf4F, required for cap-dependent translation initiation of FMRP targets (149). It was shown that an inhibitor of the elf4F complex, which creates free elf4E, increases the abundance of the elf4E-CYFIP1-FMRP complex (with a parallel decrease in the CYFIP1-WAVE complex) in Fmr1 KO mice, and the restoration of this imbalance rescues spine and memory deficits in these animals (150). Hence, studies of the Fmr1 KO rodent model have illuminated a variety of molecular mechanisms relevant to FXS, especially those pertinent to the regulation of protein synthesis, and may provide biological targets for therapeutic intervention (24), complementing ongoing clinical trials in human FXS patients (151,152).
6.2 FMRF and FMRF targets in psychiatric genomic studies

Beyond repeat expansions in the FMR1 gene, a number of rare pathogenic point mutations have been reported that cause developmental delay and intellectual disability reminiscent of FXS (153–157). Further evidence suggests that mutations in the autosomal homolog FXR2 gene might also contribute to intellectual disability (158–160). Whilst variants affecting the related FXR1 gene confer risk to schizophrenia, bipolar disorder and autism (161–165), the genetic link between FMR1 and psychiatric disorders derives from enrichment of association within the gene targets of FMRF (among which the Fragile-X family genes themselves are included).

A set of FMRF target mRNAs derived from a study of mouse cortical polyribosomes (19) have been recurrently highlighted in the literature due to their enrichment for genes associated with an array of psychiatric disorders. Through large-scale genome-wide association studies, these 842 FMRF targets have been shown to be genetically associated with schizophrenia (161,162), autism (166), major depressive disorder (167) and bipolar disorder (58). In addition to the risk conferred from common variation, this gene set is enriched for rare variants from patients with schizophrenia (168–171), autism (172) and bipolar disorder (173), de novo variants from patients with schizophrenia (174) and autism (175–177), and to a lesser extent copy number variants from patients with schizophrenia (178–180). The convergence of risk from multiple different types of genetic variant forms a strong evidence base implicating this gene set in psychiatric pathology. Conversely, FMRF targets derived from a study of human embryonic kidney cells (51) do not appear to be associated with psychiatric disorders (166,168), highlighting the tissue specificity of these relationships.

Brain FMRF targets overlap considerably with other gene sets associated with psychiatric disorders, such as genes encoding postsynaptic density proteins and those involved in calcium signalling, synaptic plasticity, learning and memory (19,52,58,181). However, despite these overlaps, the enrichment of brain FMRF targets for association with psychiatric disorders is independent (58,162,168) and proportional to the confidence of binding by FMRF (58). Moreover, in many instances, it appears that FMRF targets capture subsets of these other gene sets in which genetic association is concentrated (58). Hence, this set of genes locally regulated by FMRF during plasticity and development at the synapse may represent a collection of biological pathways important for the manifestation of a range of psychiatric disorders.
7. CYFIP1 in psychiatric disorders

7.1 15q11.2 copy number variants and Cyfip1 dosage models

The proximal long arm of human chromosome 15 (15q11.2-13.3) is a region of numerous low copy repeats that can lead to aberrant meiotic chromosomal rearrangements. These result in deletions or duplications of sections of DNA, known as copy number variants (CNVs), and occur at any of five common breakpoints (BP1-BP5) on chromosome 15 (182). Neurodevelopmental psychiatric disorders Prader-Willi syndrome (PWS) and Angelman syndrome (AS) are caused by deletions of paternal or maternal origin, respectively, and occur as either large deletions (type I, between BP1-BP3) or smaller deletions (type II, between BP2-BP3). Meanwhile, CYFIP1 is cytogenetically positioned in the non-imprinted 500kb region between BP1 and BP2 on chromosome 15 (15q11.2 interval), along with 3 additional genes: nonimprinted in Prader/Willi Angelman 1 (NIPA1) and 2 (NIPA2), and tubulin gamma complex associated protein (TUBGCP5) (183). The 15q11.2 chromosomal region was first implicated with neurodevelopmental psychiatric disorders through the observation that type I deleted PWS or AS patients, who lack the 15q11.2 interval, had more severe behavioural phenotypes compared to type II deleted patients, in which the 15q11.2 interval is intact (184,185). Later, patients were identified with deletions and duplications between BP1 and BP2, which specifically flanked the 15q11.2 interval itself (182).

Deletions or duplications of 15q11.2 are present in 1 out of 100 people that present for genetic screening, whilst incidence in the general population is likely to be nearer 1 in 500 people (186). The CNV causes patients to display language/motor deficits or delays, behavioural problems, autism and seizures (187–189), with deletions the most impactful on cognition (187) and referred to as Burnside-Butler syndrome (182,186). It was recently observed that 15q11.2 deletion patients have structural and functional changes in the brain that likely relate to the accompanying cognitive phenotypes, including a smaller left fusiform gyrus and altered activation in the left fusiform and the left angular gyri using fMRI (190). In subsequent diffusion tensor imaging (DTI) studies, 15q11.2 deletion carriers show increased fractional anisotropy (191), indicating alterations in the white matter microstructure (192). In keeping with these findings, white matter changes in 15q11.2 deletion patients closely mirror the phenotypes of FXS patients (193), suggesting a common pathogenic pathway derived from disruption of CYFIP1-FMRP protein complexes. Although the 15q11.2 deletion is not fully penetrant, as a significant
proportion of the general population are healthy carriers with no overt phenotypes (194), it is likely that subclinical cognitive phenotypes exist even in these ‘healthy’ carriers (195).

Among the genes located within the 15q11.2 locus, *CYFIP1* is widely regarded as the most likely to confer the biological and behavioural phenotypes associated with 15q11.2 BP1-BP2 CNVs (84,191). This is due, in part, to its known functional association with the FXS-relevant protein FMRP (see Sections 2, 3, 4 & 6) (31,74). Furthermore, the expression of CYFIP1 and components of the WAVE complex is disrupted in patients carrying 15q11.2 deletions (196); iPSCs derived from these patients exhibit cellular phenotypes mediated by the CYFIP1-WAVE complex (197); and the knockdown of CYFIP1, specifically, in human progenitor cells alters cytoskeletal remodelling (198). However, the biological roles of the three remaining genes within the 15q11.2 interval requires further delineation, as, like *CYFIP1*, they are all CNS expressed and their expression is altered in patients with 15q11.2 CNVs (199).

Great strides have been made in understanding the consequences of altered Cyfip1 dosage through a variety of *in vitro* and *in vivo* rodent preclinical models. For instance, the heterozygous deletion of Cyfip1 in mice results in changes in dendritic and spine morphology (74,82), which are similarly observed in a forebrain-specific conditional homozygous knockout model (83), whilst the over-expression of Cyfip1 also impinges on dendrite and spine morphology (82,200). Meanwhile, Cyfip1 appears to affect protein synthesis under basal and activity-dependent conditions. The knockdown of Cyfip1 in cortical neurons *in vitro* increases the translation of FMRP target Arc under basal conditions and also ablates the activity-dependent translation of Arc, using BDNF treatment to mimic synaptic activation (74). Similar findings were reported *in vivo* using Cyfip1 heterozygous KO mice, whereby BDNF treatment was insufficient to release the Cyfip1-FMRP complex from elf4E, preventing the formation of the elf4F complex, which subsequently prevented activity-dependent translation of Arc protein (68).

Measures of synaptic plasticity in preclinical models of altered Cyfip1 dosage have revealed elevated levels of mGluR-mediated long-term depression, which become disassociated from mRNA translation pathways (84) – findings that are reminiscent of Fmr1 KO rodent models (127,144). Over-expressing Cyfip1 in CA1 hippocampal neurons can lead to increased excitatory neurotransmission, and a concomitant decrease in GABAergic neurotransmission at inhibitory synapses, shifting the overall excitation/inhibition balance towards excessive
excitation (83). The same study also showed that the conditional, homozygous knockout of Cyfip1 in CA1 hippocampal neurons increased inhibitory GABAergic neurotransmission, along with increased expression of GABA receptors, suggesting a shift of excitation/inhibition balance towards greater inhibition (83). However, in the haploinsufficient Cyfip1 mouse model, which better models the reduced dosage of CYFIP1 in 15q11.2 deletion patients, GABAergic signalling remains unaltered in the hippocampal dentate gyrus (201).

Brain connectivity and white matter architecture appear to be especially sensitive to reduced Cyfip1 dosage. In Cyfip1 heterozygous KO mice, bilateral connectivity was shown to be reduced across multiple brain regions using resting-state functional magnetic resonance imaging (81). These alterations were likely due to changes in corpus callosal white matter architecture, measured by i) a decrease in fractional anisotropy using DTI and ii) altered levels of myelination and presynaptic function. Furthermore, many of the white matter phenotypes, including decreased fractional anisotropy, were mirrored in a comparable rat model of Cyfip1 haploinsufficiency (202). However, it is currently unclear why fractional anisotropy might be decreased in rodent models of reduced Cyfip1 dosage, but increased in 15q11.2 deletion patients. This will require further study and may alter our current perception of the effect of CNVs of the 15q11.2 interval.

In vivo models of altered Cyfip1 dosage also offer the chance to thoroughly assess changes in behaviour and cognition; prominent features in 15q11.2 deletion (and duplication) patients. Bozdagi and colleagues were the first to behaviourally assess Cyfip1 haploinsufficient mice, and found many aspects of spatial and fear learning and memory to be intact, with the exception of a rapid loss of extinction memory assessed using the inhibitory avoidance paradigm (84). Subsequent analysis of Cyfip1 heterozygous KO mice and rats have shown specific deficits in motor learning (81,203), sensorimotor gating measured by prepulse inhibition (81) and behavioural flexibility (202). Meanwhile, the over-expression of Cyfip1 results in cellular phenotypes, particularly at the dendritic level (200), but appears to have little effect on behaviour and cognition, with the exception of exaggerated fear responses (204). Overall, there is accumulating evidence that altering the dosage of Cyfip1 in preclinical models leads to profound alterations in cellular and plasticity phenotypes, alongside mild behavioural phenotypes, many of which overlap with FXS and the Fmr1 KO model (Figure 2), but also closely match the key clinical phenotypes of patients with chromosomal deletions (and duplications) of the CYFIP1-containing 15q11.2 interval.
7.2 CYFIP1 variants in psychiatric genomic studies

Genomics studies in psychiatric populations have implicated the 15q11.2 BP1-BP2 deletion with a wide range of psychiatric, neurodevelopmental disorders, including a 2- to 4-fold increased risk for schizophrenia (205,206); a finding that has been replicated in many subsequent studies (92,179,207–210). Additionally, 15q11.2 deletions, and duplications, predispose individuals to a five-fold risk of epilepsy (211), developmental and intellectual disability (212–214), ADHD (215), major depression (216) and autism (187,217) (for further review, see (182,186)).

Meanwhile, common variants in CYFIP1 have been reported to increase risk for ASD (218,219). Consistent with the genetic findings, proteomic analysis of prefrontal cortex post-mortem tissue from schizophrenia patients revealed altered levels of CYFIP1 and other proteins belonging to protein synthesis pathways (220).

The relevance of CYFIP1 to schizophrenia becomes especially apparent when considered in the wider context of its biological actions within protein complexes. CYFIP1 is involved in the regulation of ARC protein and ARC-related genes, sometimes referred to as the ‘ARC complex’ (a gene ontology-based complex). CYFIP1 was first associated with schizophrenia in studies that showed an enrichment of the ARC complex (containing 25 genes, of which CYFIP1 is one) in de novo CNV deletions from patients with schizophrenia (92). The genetic association of this ARC complex with schizophrenia has subsequently been confirmed by exome sequencing studies that assessed SNVs and indels (168,174) and larger studies of CNV deletions (178,179). Furthermore, the genetic association with schizophrenia of FMRP targets (Section 6.2), which are regulated by the CYFIP1-FMRP complex, lends additional evidence to the relevance of CYFIP1 to schizophrenia.

8. Summary of findings and future directions

FMRP and CYFIP1 are hubs for several biological pathways critical to synaptic plasticity. From preclinical models, we know that reduced expression of either CYFIP1 or FMRP results in a set of core phenotypes: altered spine and dendritic morphology, dysregulated protein synthesis and elevated long-term depression. A further layer of complexity is added when it is considered that the concerted action of FMRP and CYFIP1, as part of the CYFIP-FMRP complex, represses the translation of hundreds of FMRP targets, likely influencing multiple downstream pathways. The importance of this system to synaptic function is recurrently highlighted by genetic studies...
demonstrating the risk conferred to psychiatric disorders by variants affecting genes encoding CYFIP1, FMRP and their targets.

Nevertheless, there are many questions that still surround the biology of FMRP, CYFIP1 and FMRP targets in health and disease. For example, whilst FMRP synaptic biology is well-characterised and preclinical techniques can reverse disorder-relevant phenotypes (132,151), attempts to move these therapies into the clinic have been largely ineffective (152). This suggests that further mechanistic insights into the actions of FMRP are needed, alongside further refinement of therapeutic targets and/or strategies. Similarly, whilst FMRP targets are a disease-relevant group of mRNAs, their precise identity and biological function remains under-explored.

Meanwhile, the study of CYFIP1 has seen unprecedented advances in recent years, revealing an extensive array of synaptic roles, far beyond its initial characterisation as a binding partner to FMRP. Despite the rapid expansion of CYFIP1 studies, many fundamental questions remain and can be addressed in future studies, aided by advances in RNA sequencing, genetic-editing and proteomic technologies. Whilst extensively characterised, it is also worth noting that the behavioural phenotypes in models of Fmr1 and Cyfip1 deletion are only broadly similar, and in some cases diametrically opposed (221). These behavioural discrepancies could reflect the diversity of biological function, but might also derive from highly transient and localised interactions between these two proteins.

Penetrant risk variants affecting this biological pathway increase psychiatric vulnerability to a range of psychiatric disorders. For example, CNVs affecting CYFIP1 predispose carriers to increased risk for schizophrenia (mainly 15q11.2 deletions), autism and intellectual disability (mainly 15q11.2 duplications), and likewise FMR1 deletions predispose carriers to autism and intellectual disability. These apparently pleiotropic effects might suggest that the categorical nature of diagnoses for psychiatric disorders needs to be fundamentally re-evaluated. Indeed, at the clinic, there are many common patient symptoms that span across diagnostic categories, and patients often present with comorbidities. The genomic findings point towards a continuum of causality, whereby common biological mechanisms, influenced by a range of convergent genetic factors, span across the traditional diagnostic boundaries of psychiatric disorders. The highly tractable mechanism of CYFIP1-FMRP and the regulation of ARC, is one such biological pathway, offering a unique entry point for continued study and phenotypic rescue. The future development of novel, mechanism-based therapeutic approaches will be vital to meet the ever-growing need to treat these common, yet debilitating, psychiatric disorders.
Acknowledgements

The Authors would like to acknowledge core support received from the Neuroscience and Mental Health Research Institute, Cardiff University, UK and School of Life Sciences, Keele University, UK whilst writing this review.

Statement of Ethics

The authors have no ethical conflicts to disclose.

Disclosure Statement

The authors have no conflicts of interest to declare.

Funding Sources

The work was supported by a Wellcome Trust Strategic Award (DEFINE, 100202/Z/12/Z) and a Medical Research Council Centre Grant (GO801418). ST and NEC were supported by Cardiff University Neuroscience & Mental Health Research Institute Fellowships. ST has been additionally supported by startup funds associated with a new appointment as Lecturer at Keele University.

Author Contributions

The review was conceived by ST and written by ST and NEC. KLT, LSW and JH provided additional text, comments and support. Figures were created by ST and NEC.

References


23. De Rubeis S, Bagni C. Regulation of molecular pathways in the Fragile X Syndrome: insights into Autism


45. Doll CA, Broadie K. Activity-dependent FMRP requirements in development of the neural circuitry of learning and memory. Development. 2015;


highly associated mRNAs mediated by G-quadruplex structures formed via clustered WGGA sequences.


102. Forrest MP, Parnell E, Penzes P. Dendritic structural plasticity and neuropsychiatric disease. Nat Rev...


between breakpoint hotspots BP1 and BP2 of the Prader-Willi/Angelman syndromes deletion region that
have undergone evolutionary transposition mediated by flanking duplicons. Am J Hum Genet [Internet].

184. Butler MG, Bittel DC, Kibiryeva N, Talebizadeh Z, Thompson T. Behavioral differences among subjects with
Prader-Willi syndrome and type I or type II deletion and maternal disomy. Pediatrics. 2004 Mar;113(3 Pt
1):565–73.

185. Bittel DC, Kibiryeva N, Butler MG. Expression of 4 genes between chromosome 15 breakpoints 1 and 2 and


of proximal 15q11.2 between BP1 and BP2: a susceptibility region for neurological dysfunction including

188. Vanlerberghe C, Petit F, Malan V, Vincent-Delorme C, Bouquillon S, Boute O, et al. 15q11.2 microdeletion
(BP1-BP2) and developmental delay, behaviour issues, epilepsy and congenital heart disease: a series of 52


190. Ulfarsson MO, Walters GB, Gustafsson O, Steinberg S, Silva A, Doyle OM, et al. 15q11.2 CNV affects
cognitive, structural and functional correlates of dyslexia and dyscalculia. Transl Psychiatry. 2017


Figure Legends

Figure 1: The biological roles of synaptic FMRP and CYFIP1 proteins in postsynaptic neurons. FMRP plays a key role in negatively regulating the translation of hundreds of FMRP targets, including ARC, by forming a complex with CYFIP1, alongside initiation factor, eIF4e. The control of mRNA translation, and its repression by the CYFIP1-FMRP complex, is partly mediated through activation of upstream NMDA and mGluR5 receptors. FMRP targets such as ARC can drive changes in synaptic plasticity through regulation of AMPA receptors trafficking/internalisation and increasing actin cytoskeleton stability. Meanwhile, CYFIP1 can bind and inhibit the
WAVE regulatory complex, thereby blocking the promotion of actin cytoskeleton rearrangements. Preclinical evidence suggests that under conditions of synaptic activation, CYFIP1 redistributes between the two main complexes, with greater association with the WAVE complex and a reciprocal decrease with the FMRP complex.

**Figure 2:** Core set of overlapping phenotypes from preclinical Fmr1 and Cyfip1 deletion models. Rodent models of Fmr1 deletion (Fmr1<sup>−/−</sup>, whereby the single X-linked copy of Fmr1 is deleted in males) or heterozygous Cyfip1 deletion (Cyfip1<sup>+/−</sup>) mirror clinical populations with Fragile X Syndrome and 15q11.2 CNV deletions, respectively. Moreover, these two rodent models share a core set of functionally-related neurobiological phenotypes, including i) altered spine and dendritic morphology, ii) dysregulated protein translation and iii) elevated long-term depression. Further work is required to fully delineate the consequences of Fmr1 and Cyfip1 deletion, as well as characterise the similarities.
Common *Cyfip1* and *Fmr1* deletion phenotypes

Clinic/population: **15q11.2 deletion**  Fragile X Syndrome

Preclinical models:  

*Cyfip1*<sup>+/−</sup> KO rodents  *Fmr1*<sup>−/−</sup> KO rodents

Protein level:

![Protein level diagram](image)

- **mGluR5**
- **Increased protein translation**
- **↑ mGluR-mediated LTD**
- **Immature spine morphology**
- **Immature dendritic morphology**

Fragile X Syndrome